

CD19/CD22-targeted CAR T cells in autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation

Authors

Liu Yang,* Xinyu Wan,* Chengjuan Luo, Xiaohang Huang, Meng Su, Xia Qin, Jing Zhang, Kang An, Juan Qian, Tianyi Wang, Wenhua Shi, Jing Yang, Rujun Jia, Chengming Fei, Xiang Wang, Yanjing Tang,[#] Jing Chen[#] and Benshang Li[#]

Department of Hematology/Oncology, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China

**LY and XW contributed equally as first authors.*

[#]YT, JC and BL contributed equally as senior authors.

Correspondence:

B. LI - libenshang@scmc.com.cn

<https://doi.org/10.3324/haematol.2025.287983>

Received: November 4, 2025.

Accepted: March 9, 2026.

Early view: March 19, 2026.

©2026 Ferrata Storti Foundation

Published under a CC BY-NC license 

Supplemental Table 1 Additional clinical information.

Patient ID	Diagnosis	Gene type	Age at primary diagnosis (mos)	Age at HSCT (mos)	Gender of donor	Preparative regimen	GVHD prophylaxis regimen	Stem cell concentration (total CD34+ cells/kg)	Chimerism ratio at AIHA	DAT repeated at diagnosis, + or -
01	B-ALL	None	24.4	38.6	M	NA	NA	7.9×10 ⁶	95.8%	Yes, +
02	B-ALL	<i>KMT2A-MLLT3</i>	5.6	10.2	F	BuCy/VP16	CSA/MMF	0.5×10 ⁶	100.0%	Yes, +
03	B-ALL	<i>KMT2A-MLLT10</i>	8.2	14.8	M	Flu/Bu/Cy/Mel/TBI(3Gy)	CSA/MMF	14.5×10 ⁶ *	99.6%	Yes, +

Patient ID	HCT(%)	Lym (×10 ⁹ /L)	PLT (×10 ⁹ /L)	Ret (×10 ⁹ /L)	LDH (U/L)	Total bilirubin (umol/L)	Indirect bilirubin (umol/L)	Infection	Blood type at AIHA	GVHD at AIHA
01	15.5	0.2	67	3.8	808	40.9	22.3	parvovirus B19	O+	No
02	9.5	2.2	217	129.7	2220	60.0	48.7	None	AB+	No
03	13.7	0.1	131	8.8	631	34.4	17.2	TTV	AB+	No

Abbreviations: HSCT, hematopoietic stem cell transplantation; GVHD, graft-versus-host disease; mos, months; DAT, direct antiglobulin test; ALL, acute lymphoblastic leukemia; M, male; F, female; Bu, busulfan; Cy, cyclophosphamide; TBI, total body irradiation; Flu, Fludarabine; Mel, melphalan; Gy, Gray; CSA, cyclosporine; MMF, mycophenolate mofetil; TTV, Torque teno virus; NA, Not available.

*T cell receptor alpha/beta depleted graft.

Supplementary Figure Legends

Figure S1. Treatment process and outcomes. The entire treatment process for three patients from the primary diagnosis to the cut-off time. The color and length of each bar respectively represent the status and duration of the response. CAR T-cell infusion on day 0. BMT: Bone marrow transplantation; CART-CR: Maintain complete remission after CAR T-cell infusion.

Figure S2. Changes in cytokine levels, expansion of CAR T cells and depletion of CD19⁺ B cells in 3 patients after CAR T-cell infusion (A-C represents Pt.1, Pt.2, and Pt.3, respectively).



